|Elimination half-life||7-27 hours|
|Chemical and physical data|
|Molar mass||311.42 g/mol|
|3D model (JSmol)|
Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.
Addition of the para-fluoro atom results in a different compound that is a hybrid of femoxetine & paroxetine named FG 7080, which has a separate patent. According to the patent tables, incorporation of the fluorine atom potentiated the 5-HT affinity considerably.
- U.S. Patent 3,912,743
- U.S. Patent 4,007,196
- Lassen, Jørgen Buus; Petersen, Erling; Kjellberg, Bengt; Olsson, Sven O. (1975). "Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics". European Journal of Pharmacology. 32 (1): 108–115. doi:10.1016/0014-2999(75)90329-5. ISSN 0014-2999.
- Healy, David (2004). Let them eat Prozac : the unhealthy relationship between the pharmaceutical industry and depression. New York, NY: New York Univ. Press. pp. 26–27. ISBN 9780814736692.
- U.S. Patent 4,585,777